Kodiak Sciences Inc (KOD)
3.29
-0.45
(-12.03%)
USD |
NASDAQ |
May 17, 16:00
3.29
0.00 (0.00%)
After-Hours: 20:00
Kodiak Sciences Cash from Financing (TTM): 0.072M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 0.072M |
December 31, 2023 | 0.031M |
September 30, 2023 | 0.252M |
June 30, 2023 | 0.342M |
March 31, 2023 | 0.226M |
December 31, 2022 | 1.895M |
September 30, 2022 | 3.955M |
June 30, 2022 | 5.908M |
March 31, 2022 | 8.376M |
December 31, 2021 | 8.182M |
September 30, 2021 | 622.31M |
Date | Value |
---|---|
June 30, 2021 | 621.08M |
March 31, 2021 | 619.06M |
December 31, 2020 | 717.38M |
September 30, 2020 | 400.44M |
June 30, 2020 | 399.92M |
March 31, 2020 | 399.43M |
December 31, 2019 | 299.69M |
September 30, 2019 | 85.88M |
June 30, 2019 | 84.54M |
March 31, 2019 | 83.84M |
December 31, 2018 | 116.47M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.031M
Minimum
Dec 2023
717.38M
Maximum
Dec 2020
213.95M
Average
46.46M
Median
Cash from Financing (TTM) Benchmarks
Avalo Therapeutics Inc | 119.91M |
Regeneron Pharmaceuticals Inc | -1.420B |
Ligand Pharmaceuticals Inc | -46.99M |
iBio Inc | 10.68M |
Dare Bioscience Inc | 14.35M |